Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q2 2021 · 10-Q
Revenue$125.00K$125.00K−93.1% vs Q2 2020 Net Income-$1.66M-$1.66MN/M vs Q2 2020 EPS Diluted-$0.04-$0.04N/M vs Q2 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,462,000N/M Free Cash Flowderived-$2,747,000N/M Margins · derivedGross margin20.8%+19.3 pt vs Q2 2020
Operating margin-1340.8%−1270.1 pt vs Q2 2020
Net margin-1325.6%−1260.9 pt vs Q2 2020
ended Sep 30, 2020 · filed Nov 20, 2020 · 51 d after period end